Table 1.
Descriptive statistics on 948 MPN patients.
| Total | Medication | ||||||
|---|---|---|---|---|---|---|---|
| Characteristics | n = 948 | None, n = 171 | HU, n = 407 | RUX, n = 170 | Combinations, n = 53 | Interferon, n = 57 | Othera, n = 90 |
| Age, years—median (range) | 67.0 (18–99) | 58.0 (18–86) | 73.0 (18–99) | 64.5 (24–88) | 63.5 (39–85) | 51.0 (25–80) | 67.0 (20–90) |
| Sex | |||||||
| Female—no. (%) | 431 (50.4) | 72 (16.7) | 211 (49.0) | 64 (14.8) | 26 (6.0) | 27 (6.3) | 31 (7.2) |
| Male—no. (%) | 425 (49.6) | 79 (18.6) | 82 (42.8) | 62 (14.6) | 20 (4.7) | 25 (5.9) | 57 (13.4) |
| MPN Subtype | |||||||
| PV—no. (%) | 287 (30.3) | 47 (16.4) | 140 (48.8) | 62 (21.6) | 15 (5.2) | 13 (4.5) | 10 (3.5) |
| ET—no. (%) | 388 (40.9) | 62 (16.0) | 211 (54.4) | 23 (5.9) | 22 (5.7) | 34 (8.7) | 36 (9.3) |
| MF—no. (%) | 223 (23.5) | 54 (24.2) | 48 (21.5) | 82 (36.8) | 14 (6.3) | 10 (4.5) | 15 (6.7) |
| MPN-U—no. (%) | 24 (2.5) | 7 (29.2) | 8 (33.3) | 3 (12.5) | 2 (8.3) | 0 | 4 (16.7) |
| CML—no. (%) | 26 (2.8) | 1 (3.8) | 25 (96.2) | ||||
| Driver mutation | |||||||
| JAK2—no. (%) | 682 (78.3) | 116 (17.0) | 338 (49.6) | 131 (19.2) | 32 (4.7) | 33 (4.8) | 32 (4.7) |
| MPL—no. (%) | 26 (3.0) | 9 (34.6) | 9 (34.6) | 2 (7.7) | 1 (3.9) | 2 (7.7) | 3 (11.5) |
| CALR—no. (%) | 131 (15.0) | 33 (25.2) | 30 (22.9) | 19 (14.5) | 14 (10.7) | 17 (13.0) | 18 (13.7) |
| Triple negative—no. (%) | 32 (3.7) | 5 (15.6) | 14 (43.8) | 7 (21.9) | 1 (3.1) | 2 (6.2) | 3 (9.4) |
| Infections | |||||||
| ≥1 infection last 12 mo—no. (%) | 479 (50.5) | 95 (55.6) | 150 (36.9) | 116 (68.2) | 37 (69.8) | 35 (61.4) | 46 (51.1) |
| Upper respiratory—no. (%) | 338 (35.7) | 72 (42.1) | 106 (26.0) | 83 (48.4) | 20 (37.7) | 23 (40.4) | 34 (37.8) |
| Pneumonia—no. (%) | 37 (3.9) | 8 (4.7) | 10 (2.5) | 12 (7.1) | 3 (5.7) | 0 | 3 (3.8) |
| GI—no. (%) | 135 (14.2) | 33 (19.3) | 18 (4.4) | 40 (23.5) | 15 (28.3) | 15 (26.3) | 12 (15.4) |
| Herpes virus—no. (%) | 144 (15.2) | 34 (19.9) | 29 (7.1) | 43 (25.3) | 14 (26.4) | 13 (22.8) | 11 (12.2) |
| Skin—no. (%) | 70 (7.4) | 10 (5.8) | 18 (4.4) | 21 (12.4) | 5 (9.4) | 4 (7.0) | 8 (10.3) |
| UTI—no. (%) | 43 (4.5) | 7 (4.1) | 14 (3.4) | 16 (9.4) | 3 (5.7) | 2 (3.5) | 1 (1.3) |
| Other—no. (%) | 52 (5.5) | 6 (3.5) | 22 (5.4) | 12 (7.1) | 3 (5.7) | 4 (7.0) | 4 (5.1) |
| Treatment, frequency | |||||||
| Outpatient/ambulatory | |||||||
| 0—no. (%) | 123 (25.8) | 33 (35.1) | 37 (24.8) | 28 (24.3) | 6 (16.2) | 10 (28.6) | 9 (19.6) |
| 1—no. (%) | 191 (40.1) | 31 (32.9) | 78 (52.4) | 36 (31.3) | 11 (29.7) | 13 (37.1) | 22 (47.8) |
| >1—no. (%) | 162 (34.1) | 30 (32.0) | 34 (22.8) | 51 (44.4) | 20 (54.1) | 12 (34.3) | 15 (32.6) |
| inpatient/hospitalized | |||||||
| 0—no. (%) | 421 (88.6) | 85 (90.4) | 131 (87.9) | 102 (87.9) | 31 (83.8) | 35 (100) | 0 |
| 1—no. (%) | 41 (8.6) | 6 (6.4) | 14 (9.4) | 10 (8.6) | 6 (16.2) | 0 | 0 |
| >1—no. (%) | 13 (2.8) | 3 (3.2) | 4 (2.7) | 4 (3.5) | 0 | 0 | 0 |
| Prophylaxis | |||||||
| Antibiotic—no. (%) | 13 (1.4) | 4 (2.3) | 4 (1.0) | 3 (1.8) | 0 | 0 | 2 (2.2) |
| Antiviral—no. (%) | 5 (0.5) | 0 | 0 | 4 (2.4) | 0 | 0 | 1 (1.1) |
| Antifungal—no. (%) | 8 (0.8) | 1 (0.6) | 0 | 3 (1.8) | 1 (1.9) | 2 (3.5) | 1 (1.1) |
| Vaccinations | |||||||
| Influenza—no. (%) | 364 (38.4) | 41 (24.0) | 175 (43.0) | 70 (41.2) | 26 (49.0) | 18 (31.6) | 34 (37.8) |
| Pneumococci—no. (%) | 111 (11.7) | 5 (2.9) | 69 (17.0) | 19 (11.2) | 4 (7.5) | 6 (10.5) | 8 (8.9) |
| Meningococci—no. (%) | 24 (2.5) | 3 (1.8) | 6 (1.5) | 6 (3.5) | 1(1.9) | 5 (8.8) | 3 (3.3) |
| Other—no. (%) | 122 (12.9) | 23 (13.5) | 19 (4.7) | 50 (29.4) | 4 (7.5) | 18 (31.6) | 8 (8.9) |
| Diagnostic testing | |||||||
| Hepatitis—no. (%) | 147 (15.5) | 25 (14.6) | 27 (6.6) | 53 (31.2) | 15 (28.3) | 17 (29.8) | 10 (11.1) |
| Tuberculosis—no. (%) | 81 (8.5) | 17 (9.9) | 13 (3.2) | 30 (17.6) | 8 (15.0) | 9 (15.8) | 4 (4.4) |
| Toxoplasmosis—no. (%) | 69 (7.3) | 13 (7.6) | 10 (2.5) | 26 (15.3) | 6 (11.3) | 10 (17.5) | 4 (4.4) |
mo months, no. number, PV polycythemia vera, ET essential thrombocythemia, MF myelofibrosis, MPN-U MPN unclassifiable, CML chronic myelogenous leukemia, GI gastro-intestinal, UTI urinary tract infection, HU hydroxyurea, RUX ruxolitinib.
aOther: TKI; chemotherapeutic agents; anagrelide. Combination therapies included RUX plus either agent: hydroxyurea, pomalidomide, MDM2-inhibitors, BET-inhibitors, or interferon alpha.